Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment reporting

Analytics

Phase 3
5(71.4%)
Phase 2
2(28.6%)
7Total
Phase 3(5)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT05959421Phase 3Withdrawn

Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure

Role: lead

NCT05293080Phase 3Recruiting

Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE

Role: lead

NCT03104842Phase 2Active Not Recruiting

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

Role: lead

NCT05675319Phase 3Terminated

Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Role: lead

NCT02170090Phase 3Active Not Recruiting

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

Role: lead

SYF85013e0adb6849e69740eb5fcd758bf2Phase 2Unknown

A study to evaluate the safety and efficacy of mebendazole in combination with low-dose Ara-C in elderly patients with relapsed/refractory acute myeloid leukemia (MAIL)

Role: lead

SYFbdf9a690830a4d43afc4c6c8b5216cdaPhase 3Recruiting

Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants

Role: lead

All 7 trials loaded